Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Excessive Drug Pricing: What It Is, And What It Isn't

Executive Summary

It's difficult to know exactly how to define "excessive" or "unfair" pricing where pharmaceutical products are concerned, and many factors have to be taken into account. Even the EU Commission and competition authorities may be reluctant to pursue cases of alleged price gouging, lawyer David Hull told Informa's recent EU Pharma Law Forum in Brussels.

You may also be interested in...

UK Decision Soon On Pfizer/Flynn’s “Excessive” Phenytoin Price Rises

As the Mylan EpiPen controversy in the US draws yet more attention to price increases on certain pharmaceutical products, an imminent decision by the UK competition authorities should help to clarify what should constitute “excessive” and “unfair” pricing.

Handling Drug Price Spikes: A Sad Place To Be

When Valeant Pharmaceuticals International Inc. suddenly raised the prices of two critical drugs in the hospital setting, Nitropress (sodium nitroprusside) and Isuprel (isoprenaline), facilities had to find a way to deal with ensuring they had those vital medicines available, but doing so without breaking the bank.

UK Authorizes Use Of Unlicensed Flu Vaccine

A legislative provision under which future COVID-19 vaccines can be made available in the UK before they are approved is also being used to offer an unlicensed flu vaccine that officials say has undergone full safety, efficacy and quality tests.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts